Roche bets up to $2.3B in Hanmi pact for next-gen weight loss drug
BioSpace
Roche, through its subsidiary Genentech, will gain access to the investigational asset HM17321, which is designed to not only elicit weight loss but also improve lean mass.
pharminent
August 24, 2026 (Last updated: September 1, 2026)
BioSpace
Roche, through its subsidiary Genentech, will gain access to the investigational asset HM17321, which is designed to not only elicit weight loss but also improve lean mass.
